洛铂联合多西他赛与多西他赛单药二线治疗晚期非小细胞肺癌的比较

目的 探讨洛铂联合多西他赛方案与单药多西他赛方案二线治疗非小细胞肺癌（NSCLC）的疗效和毒副反应。方法 将符合入组标准的42例晚期NSCLC患者分为观察组（n=15）和对照组（n=27）。观察组方案：多西他赛75mg／m2静滴，d1；洛铂30mg／m2静滴，d2，21～28天为1周期。对照组方案：多西他赛75mg／m2静滴，d1，21～28天为1周期。每组至少治疗3个周期，2个周期后评价疗效。结果 42例患者均可评价疗效。观察组的疾病控制率和有效率分别为73.3％（11／15）和26.7％（4／15），对照组分别为63.0％（17／27）和22.2％（6／27），两组比较差异均无统计学意义（P＞005）。观察组的平均生存时间为18.0个月，中位生存时间未达，较对照组的14.0个月长（P＜0.05）。观察组的中位无疾病进展时间为11.0个月，对照组为7.8个月，两组比较差异无统计学意义（P＞0.05）。在中性粒细胞减少、贫血和消化道反应的发生率方面，两组差异均无统计学意义（P＞0.05）；而观察组血小板减少的发生率高于对照组（P=0.047）。结论 洛铂联合多西他赛与单药多西他赛二线治疗NSCLC的近期疗效、生存期和毒副反应基本相似，需要进一步观察。

The efficacy of lobaplatin combined with docetaxel versus docetaxel alone as the second-line treatment for advanced non-small cell lung cancer

Objective To compare the clinical efficacy and toxicity of single-agent docetaxel and lobaplatin combined with docetaxel as the second-line chemotherapy for patients with advanced non-small cell lung cancer （NSCLC）. Methods Fourty-two pa- tients with advanced NSCLC were divided into observation group and control group. Observation group （ n = 27 ） ： lobaplatin 30 mg/m2 iv, d2 ; docetaxel 75 mg/m： iv, d1. Control group （n = 27 ） ： doeetaxel 75 mg/m2iv, dI. Twenty-one to twenty-eight days was a cycle for the two regimens and each patient was treated at least 3 cycles. The efficacy was evaluated after two cycles. Results All the patients could be evaluated. The disease control rate and response rate of observation group were 73.3% （ll/15）and 26.7% （4/15） , and in control group were 63.0% （ 17/27 ） and 22. 2% （6/27）. There was no statistical difference between the two groups. The mean surviv- al for observation group was 18.0 months, which was longer than the median survival 14.0 months of control group（P 〈0.05）. The median progression-free survival of observation group and control group were 11.0 months and 7. 8 months （ P 〉 0. 05 ）. There was no significantly statistical differentce （ P 〉 0. 05 ） in neutropenia, anemia and gastrointestinal reactions between the two groups ; the rate of thrombocytopenia was higher in observation group （ P = 0. 047 ）. Conclusion The efficacy, survival and toxicity between lobaplatin combined with docetaxel and single-agent docetaxel was similar as the second-line treatment for patients with advanced NSCLC, and worth further study.